

# Prognostic Significance of $^{18}\text{F}$ -FDG and $^{99\text{m}}\text{Tc}$ -Methylene Diphosphonate Uptake in Primary Osteosarcoma

Christiane Franzius, MD<sup>1</sup>; Stefan Bielack, MD<sup>2</sup>; Silke Flege<sup>2</sup>; Joachim Sciuk, MD<sup>1</sup>; Heribert Jürgens, MD<sup>2</sup>; and Otmar Schober, MD, PhD<sup>1</sup>

<sup>1</sup>Department of Nuclear Medicine, Münster University Hospital, Münster, Germany; and <sup>2</sup>Department of Pediatric Hematology and Oncology, Münster University Hospital, Münster, Germany

The purpose of this retrospective analysis was to evaluate the prognostic significance of both initial glucose metabolism as measured by  $^{18}\text{F}$ -FDG PET and osteoblastic activity as measured by  $^{99\text{m}}\text{Tc}$ -methylene diphosphonate (MDP) bone scintigraphy in osteosarcoma. **Methods:** In 29 patients (18 male, 11 female; age range, 5–41 y) with primary osteosarcoma,  $^{18}\text{F}$ -FDG uptake and  $^{99\text{m}}\text{Tc}$ -MDP uptake were measured semiquantitatively (average and maximum tumor-to-nontumor ratios [ $\text{T}/\text{NT}_{\text{av}}$  and  $\text{T}/\text{NT}_{\text{max}}$ , respectively]) using PET and bone scintigraphy at the time of diagnosis. After chemotherapy, the patients underwent surgery for their primary tumor, and the response was determined histologically. Cumulative overall survival and event-free survival were determined by clinical and imaging follow-up of 7–72 mo (median, 28 mo). **Results:** Clinical and imaging follow-up revealed that the disease relapsed or failed to achieve complete remission in 9 patients and that 6 patients died of the disease. Both overall and event-free survival were significantly better in patients with a low  $^{18}\text{F}$ -FDG  $\text{T}/\text{NT}_{\text{max}}$  (less than the median) than in patients with a high  $^{18}\text{F}$ -FDG  $\text{T}/\text{NT}_{\text{max}}$  (at least the median). The negative relationship of  $^{18}\text{F}$ -FDG  $\text{T}/\text{NT}_{\text{av}}$ ,  $^{99\text{m}}\text{Tc}$ -MDP  $\text{T}/\text{NT}_{\text{max}}$ , and  $^{99\text{m}}\text{Tc}$ -MDP  $\text{T}/\text{NT}_{\text{av}}$  with overall and event-free survival did not reach a level of significance.  $^{18}\text{F}$ -FDG uptake values correlated moderately and positively with  $^{99\text{m}}\text{Tc}$ -MDP uptake values, but a level of significance was reached only between  $^{18}\text{F}$ -FDG  $\text{T}/\text{NT}_{\text{max}}$  and  $^{99\text{m}}\text{Tc}$ -MDP  $\text{T}/\text{NT}_{\text{av}}$ . **Conclusion:** The initial glucose metabolism of primary osteosarcoma as measured by  $^{18}\text{F}$ -FDG PET using  $\text{T}/\text{NT}_{\text{max}}$  provides prognostic information. High  $^{18}\text{F}$ -FDG uptake correlates with poor outcome. Thus,  $^{18}\text{F}$ -FDG uptake may be complementary to other well-known factors in judging the prognosis in osteosarcoma.

**Key Words:**  $^{18}\text{F}$ -FDG PET;  $^{99\text{m}}\text{Tc}$ -methylene diphosphonate bone scintigraphy; osteosarcoma; prognosis; glucose metabolism

**J Nucl Med 2002; 43:1012–1017**

**M**usculoskeletal malignancies usually metabolize glucose at an increased rate, and  $^{18}\text{F}$ -FDG PET can thus be used for grading and characterizing their biologic aggressiveness (1,2). In osteosarcoma, measurement of changes in glucose metabolism using  $^{18}\text{F}$ -FDG PET appears to be a good non-invasive way to determine the response to neoadjuvant chemotherapy (3,4). More recently, glucose metabolism at the time of diagnosis has been shown to predict prognosis in some types of solid tumors, such as lung cancer and pancreatic carcinoma (5–9). A systematic evaluation of the prognostic value of initial glucose metabolism in osteosarcoma has not yet been reported. Furthermore, for tumor cells in other malignancies, specific capabilities such as uptake of  $^{131}\text{I}$  indicate differentiation and imply a good prognosis (10). In the case of osteosarcoma, the production of primitive osseous matrix is a specific capability of the tumor cells. The aim of this retrospective analysis of osteosarcoma patients was to evaluate the prognostic importance of initial glucose metabolism as measured by  $^{18}\text{F}$ -FDG PET and of osteoblastic activity as measured by  $^{99\text{m}}\text{Tc}$ -methylene diphosphonate (MDP) bone scintigraphy.

## MATERIALS AND METHODS

### Patient Population

Primary osteosarcoma was diagnosed in all patients, and all underwent both  $^{18}\text{F}$ -FDG PET and bone scintigraphy at the time of the initial diagnosis, before beginning chemotherapy. The exclusion criteria were surgery before the nuclear medicine examinations or a pathologic fracture of the primary tumor site. Patients with primary metastatic disease were not excluded. Within a 5¼-y period, 29 consecutive patients fulfilled these criteria (18 males, 11 females; age range, 5–41 y; median age, 14 y). All patients had high-grade osteosarcoma. Further detailed clinical information is given in Table 1. The size of the primary tumor was determined by morphologic imaging (MRI or CT). After biopsy and histologic confirmation, all patients underwent neoadjuvant chemotherapy with doxorubicin, high-dose methotrexate, cisplatin, and ifosfamide according to the respective Cooperative Osteosarcoma Study (COSS) protocols (COSS-86c,  $n = 7$ ; COSS-96,  $n = 22$ ), followed by surgical resection of the primary tumor site. Response

Received Nov. 26, 2001; revision accepted Mar. 27, 2002.  
For correspondence or reprints contact: Christiane Franzius, MD, Department of Nuclear Medicine, Münster University Hospital, Albert-Schweitzer-Strasse 33, 48149 Münster, Germany.  
E-mail: franziu@uni-muenster.de

**TABLE 1**  
Clinical, Imaging, and Follow-Up Patient Data

Age (y)	Sex	Primary tumor site	Histology	<sup>18</sup> F-FDG PET		Skeletal scintigraphy		Period (mo)	Follow-up	
				T/NT <sub>av</sub>	T/NT <sub>max</sub>	T/NT <sub>av</sub>	T/NT <sub>max</sub>		Course	Current status
5	F	Proximal tibia	Fibroblastic	3.9	10.3	6.9	18.2	16	CR1	CR
5	M	Distal femur	Osteoblastic	4.4	3.7	7.8	—	68	CR1	CR
6	M	Distal femur	Osteoblastic	6.4	22.8	5.0	14.6	16	CR1, R1 (o)	DFD
8	M	Distal femur	Fibroblastic	7.7	32.4	5.9	19.2	7	CR1	CR
9	F	Proximal tibia	Small cell	4.0	9.4	6.0	18.2	49	CR1	CR
9	M	Distal femur	Osteoblastic	4.8	7.5	4.6	—	70	CR1	CR
9	M	Proximal femur*	Osteoblastic	4.5	12.6	3.3	—	28	CR1, R1 (p, o)	DFD
11	M	Distal femur	Osteoblastic	4.8	8.3	2.6	—	72	CR1	CR
11	M	Proximal tibia	Fibroblastic	3.7	10.6	2.8	12.8	28	CR1	CR
11	M	Ulna	Teleangiectatic	5.3	23.1	9.1	31.7	14	CR1	CR
12	F	Distal femur	Osteoblastic	5.1	14.7	2.9	—	64	CR1	CR
12	M	Proximal tibia	No diff.	7.9	22.1	2.7	6.5	44	CR1, R1 (p), CR2	CR
13	F	Distal femur	No diff.	9.7	32.8	5.0	12.9	27	CR1	CR
13	M	Distal femur	Fibroblastic	3.7	8.3	5.7	5.9	33	CR1	CR
14	F	Distal tibia	Fibroblastic	11.0	33.0	3.9	20.5	18	CR1	CR
14	M	Distal femur	Sclerotic	2.7	8.6	2.8	—	41	CR1, R1 (l, p), CR2, R2 (p)	DFD
14	M	Proximal tibia	Osteoblastic	2.6	5.5	3.2	—	65	CR1	CR
15	F	Distal femur	Osteoblastic	1.8	4.4	2.1	3.7	41	CR1	CR
15	F	Distal femur	Osteoblastic	19.2	96.3	16.2	15.7	7	CR1	CR
15	F	Humerus*	Osteoblastic	2.9	9.8	17.3	40.9	20	CR1	CR
15	M	Proximal tibia	Chondroblastic	3.8	7.7	3.5	8.9	42	CR1	CR
16	M	Distal femur	Osteoblastic	8.2	39.8	9.0	13.6	25	CR1, R1 (o, p)	AD
17	M	Femur*	No diff.	6.5	18.4	7.7	15.4	30	CR1	CR
17	M	Proximal tibia	Fibroblastic	1.6	3.2	2.9	13.8	21	CR1	CR
21	M	Proximal tibia	Fibroblastic	4.4	26.6	12.7	37.6	34	CR1, R1 (l, p)	AD
22	M	Fibula	No diff.	6.8	23.3	21.8	49.3	45	CR1, R1 (p, o)	DFD
23	F	Distal femur*	Osteoblastic	3.5	10.4	22.8	60.3	11	CR1	CR
35	F	Distal femur	Osteoblastic	9.0	26.5	14.7	40.2	18	CR1, R1 (p)	DFD
41	F	Pelvis*	Osteoblastic	1.7	18.1	4.0	10.9	26	No CR	DFD

\*Primary metastatic disease.

CR = complete remission; R = relapse; o = osseous; DFD = dead from disease; p = pulmonary; no diff. = no differentiation possible; l = local; AD = alive, with disease.

was assessed histologically according to the classification of Salzer-Kuntschik et al. (11). A good response was assumed when tumor viability was <10%. Cumulative overall survival and event-free survival were determined by clinical and imaging follow-up of 7–72 mo (median, 28 mo).

### Imaging Techniques

<sup>18</sup>F-FDG PET scans were acquired as previously described (12). The patients had been fasting for at least 5 h before the <sup>18</sup>F-FDG injection. No patient was known to have diabetes mellitus or a pathologic glucose tolerance. Blood glucose levels at the time of injection were <6.66 mmol/L in all patients. The first 20 <sup>18</sup>F-FDG PET examinations were done without attenuation correction. For the remaining 9 examinations, whole-body emission–transmission scanning was performed.

The procedure for planar 3-phase <sup>99m</sup>Tc-MDP bone scintigraphy has been described in detail (3). Total body imaging (anterior and posterior views) was performed 3–4 h after the injection using a Bodyscan (Siemens, Erlangen, Germany) at a speed of 15 cm/min. Additionally, static planar images of the primary tumor site in 2 planes were acquired. Low-energy, high-resolution collimators were used.

All patients, or the parents or legal guardians of minors, gave informed consent to all <sup>18</sup>F-FDG PET and bone scintigraphy examinations, to participation in the COSS therapy studies, and to all surgical interventions.

### Imaging Analysis

The images were analyzed by observers who were unaware of the clinical and histopathologic data. Only the primary tumor site and the age and sex of the patients were known by the observers.

On the <sup>18</sup>F-FDG PET coronal slice expressing the highest uptake of the primary tumor site, rectangular regions of interest (ROIs) were manually defined using a 3-dimensional display technique (MPI-Tool; Advanced Tomo Vision, Erfstadt, Germany) (13). The boundaries of the ROIs were just within the apparent hypermetabolic zone of the tumor. ROIs of identical configuration were placed on the analogous site of the contralateral extremity. Tumor-to-nontumor ratios (T/NT) were calculated using the average (T/NT<sub>av</sub>) and maximum (T/NT<sub>max</sub>) values within each tumor ROI and the average value within the nontumor ROI (2–4,14).

On bone scintigrams, identical rectangular ROIs were manually placed around clearly visible tumor activity and on the analogous

site of the contralateral extremity. Epiphyseal plate activity was omitted.  $T/NT_{av}$  was calculated in the usual way for all patients, and  $T/NT_{max}$  was calculated additionally for 23 patients (3,15,16).

### Statistical Analysis

For each parameter, the median, 25th, and 75th percentiles are given. The significance of the difference in medians between 2 groups was tested using the 2-tailed Mann-Whitney test (17). The significance of the correlation between 2 parameters was assessed using Spearman rank correlation (18). Probability values  $< 0.05$  were considered significant. The follow-up period was calculated from the time of diagnosis. An event was defined as local or distant relapse of disease or failure to achieve complete remission. Survival was analyzed using the Kaplan–Meier method (19). The log-rank test was used to compare actuarial survival probabilities (20). The median value was chosen as the cutoff level for all parameters to establish a low-uptake group and a high-uptake group (21).

## RESULTS

### $^{18}F$ -FDG and $^{99m}Tc$ -MDP Uptake

All primary osteosarcomas were clearly visible on both the  $^{18}F$ -FDG PET images and the bone scintigrams. The individual  $^{18}F$ -FDG and  $^{99m}Tc$ -MDP uptake values are given in Table 1.

The median  $^{18}F$ -FDG  $T/NT$ s for the whole patient group were 4.5 for  $T/NT_{av}$  (25th percentile, 3.7; 75th percentile, 6.8) and 12.6 for  $T/NT_{max}$  (25th percentile, 8.3; 75th percentile, 23.3) ( $r = 0.80$ ;  $P < 0.001$ ).

The median  $^{99m}Tc$ -MDP  $T/NT$ s were 6.6 for  $T/NT_{av}$  (25th percentile, 3.2; 75th percentile, 9.0) and 15.5 for  $T/NT_{max}$  (25th percentile, 12.8; 75th percentile, 28.9). A significant positive correlation was found between  $^{99m}Tc$ -MDP  $T/NT_{av}$  and  $^{18}F$ -FDG  $T/NT_{max}$  ( $r = 0.50$ ;  $P = 0.005$ ), but only a tendency toward a positive correlation was found between


$^{99m}Tc$ -MDP  $T/NT_{av}$  and  $^{18}F$ -FDG  $T/NT_{av}$  ( $r = 0.36$ ;  $P > 0.05$ ), between  $^{99m}Tc$ -MDP  $T/NT_{max}$  and  $^{18}F$ -FDG  $T/NT_{av}$  ( $r = 0.21$ ;  $P > 0.05$ ), and between  $^{99m}Tc$ -MDP  $T/NT_{max}$  and  $^{18}F$ -FDG  $T/NT_{max}$  ( $r = 0.33$ ;  $P > 0.05$ ). These 3 correlations did not reach statistical significance.

### Histology, Regression Grade, and Size


Histologically, the response to chemotherapy was good in 20 patients and poor in 9 patients. No significant difference in  $^{18}F$ -FDG  $T/NT_{av}$ ,  $^{18}F$ -FDG  $T/NT_{max}$ ,  $^{99m}Tc$ -MDP  $T/NT_{av}$ , or  $^{99m}Tc$ -MDP  $T/NT_{max}$  median values was found between the various osteosarcoma histology subtypes or the different regression grades. Additionally, no significant correlation was found between the size of the primary tumor and any of the semiquantitative uptake values ( $^{18}F$ -FDG  $T/NT_{av}$ ,  $^{18}F$ -FDG  $T/NT_{max}$ ,  $^{99m}Tc$ -MDP  $T/NT_{av}$ , or  $^{99m}Tc$ -MDP  $T/NT_{max}$ ).

### Survival

Clinical and imaging follow-up revealed an event in 9 patients (relapse of disease in 8 patients, failure to achieve complete remission in 1 patient). Six patients died of their disease (Table 1). For the whole patient group, actuarial overall survival and event-free survival at 72 mo were 0.63 and 0.61, respectively (Figs. 1A and 1B). Only  $^{18}F$ -FDG  $T/NT_{max}$  ( $^{18}F$ -FDG  $T/NT_{max} \geq$  median vs.  $^{18}F$ -FDG  $T/NT_{max} <$  median) correlated significantly with both overall survival ( $P < 0.05$ ) and event-free survival ( $P < 0.005$ ) (Figs. 2C and 2D). The influence of tumor  $^{18}F$ -FDG uptake was explored for various  $T/NT_{max}$  cutoff values. Using  $^{18}F$ -FDG  $T/NT_{max}$ , dichotomization with a broad range of  $T/NT_{max}$  values gave significantly discriminative log-rank probability values for both overall survival (30th percentile to 50th



**FIGURE 1.** Disease outcome for whole patient group as determined by Kaplan–Meier analyses using overall survival (A) and event-free survival (B). Tick marks indicate individual follow-up period.




**FIGURE 2.** Disease outcome for  $^{99m}\text{Tc}$ -MDP  $\text{T}/\text{NT}_{\text{max}}$  (overall survival [A] and event-free survival [B]) and  $^{18}\text{F}$ -FDG  $\text{T}/\text{NT}_{\text{max}}$  (overall survival [C] and event-free survival [D]) as determined by Kaplan–Meier analyses. Median levels were used as cutoff values. Tick marks indicate individual follow-up period.

percentile of  $^{18}\text{F}$ -FDG  $\text{T}/\text{NT}_{\text{max}}$ ) and event-free survival (30th percentile to 60th percentile of  $^{18}\text{F}$ -FDG  $\text{T}/\text{NT}_{\text{max}}$ ) (Figs. 3A and 3B). Using the other semiquantitative uptake values ( $^{18}\text{F}$ -FDG  $\text{T}/\text{NT}_{\text{av}}$ ,  $^{99m}\text{Tc}$ -MDP  $\text{T}/\text{NT}_{\text{av}}$ , and  $^{99m}\text{Tc}$ -MDP  $\text{T}/\text{NT}_{\text{max}}$ ), there was the tendency toward a worse prognosis with higher uptake rates, but the level of significance was reached neither with the median cutoff (Figs. 2A and 2B) nor with any other cutoff (10th percentile to 90th percentile of uptake values).

## DISCUSSION

This study showed that initial  $^{18}\text{F}$ -FDG  $\text{T}/\text{NT}_{\text{max}}$  values clearly discriminated between osteosarcoma patients with a high probability of overall and event-free survival and osteosarcoma patients with a poor prognosis.

Previous studies have shown that pretreatment  $^{18}\text{F}$ -FDG PET can predict tumor behavior and prognosis for a variety of other tumor types (5–9,22). However, some of these studies are hindered by the heterogeneity of their treatment options. In a retrospective study by Ahuja et al. (6) of patients with non–small cell lung cancer, patients with stages I–IIIA underwent complete tumor resection whereas patients with stages IIIB–IV received chemotherapy or radiation. In a series of primary breast cancer patients, mastectomy was performed on some patients whereas others had breast-conserving therapy (22). The different therapeutic regimens, chosen because there were tumors in different stages, might have caused a bias in those studies. In this study, all patients received the same treatment: neoadjuvant chemotherapy followed by surgical removal of the primary



**FIGURE 3.** Relationship between various  $^{18}\text{F}$ -FDG  $\text{T}/\text{NT}_{\text{max}}$  cutoff values and their discriminative value for both overall survival (A) and event-free survival (B) as assessed by log-rank test. Broad range of  $^{18}\text{F}$ -FDG  $\text{T}/\text{NT}_{\text{max}}$  ratios gave significant log-rank probability values ( $P < 0.05$ ).

tumor. Furthermore, knowledge of the  $^{18}\text{F}$ -FDG uptake of the primary tumor site is not likely to have influenced the choice of therapeutic management, because all  $^{18}\text{F}$ -FDG PET examinations were performed for the purpose of individual staging.

In recent studies, a positive correlation between  $^{18}\text{F}$ -FDG uptake and grading has been shown for the heterogeneous group of bone tumors. Although definite differentiation between benign and malignant bone tumors and between the different grades is not possible using  $^{18}\text{F}$ -FDG PET, high  $^{18}\text{F}$ -FDG uptake values measured either semiquantitatively (standardized uptake value or  $\text{T}/\text{NT}$ ) or absolutely (metabolic rate of glucose consumption) indicate biologically aggressive lesions (1,2,23). In the current analysis, all patients had high-grade osteosarcoma. The  $^{18}\text{F}$ -FDG uptake values varied within a wide range, and some were even very low, as is concordant with those studies (1,2,23).  $^{18}\text{F}$ -FDG uptake not only reflects the biologic characteristics of bone tumors but also was found to be of prognostic significance in osteosarcoma. It is not surprising that prognostic discrimination is best when the peak values ( $^{18}\text{F}$ -FDG  $\text{T}/\text{NT}_{\text{max}}$ ) within the tumor ROIs are used, because the cellular composition of sarcomas is frequently heterogeneous and the most aggressive sarcoma cells seem to determine the outcome of the patient. The prognostic impact of standardized uptake value could not be evaluated in this study because  $^{18}\text{F}$ -FDG PET was performed with transmission scanning for only a few patients. Because most of the primary osteosarcoma tumors were in the extremities ( $n = 28$ ), with the exception of 1 pelvic primary tumor, attenuation was not expected to play a major role.

Additionally, the results of this study showed a trend toward an association between low  $^{99\text{m}}\text{Tc}$ -MDP uptake and good prognosis. However, levels of significance were not reached. This trend fits in with the moderately positive correlation between  $^{18}\text{F}$ -FDG and  $^{99\text{m}}\text{Tc}$ -MDP uptake values. The production of primitive osseous matrix is a specific capability of osteosarcoma cells. In some solid tumor types, such as differentiated thyroid cancer, the specific capabilities of the tumor cells are a sign of cellular differentiation (10,24,25) and correlate positively with prognosis (10). In contrast, in some other tumor types, high  $^{18}\text{F}$ -FDG uptake indicates dedifferentiation and is associated with poor outcome (10). In cases of osteosarcoma, a negative association between the production of primitive osseous matrix as measured by  $^{99\text{m}}\text{Tc}$ -MDP bone scintigraphy and glucose metabolism as measured by  $^{18}\text{F}$ -FDG PET was not found. One reason might be that  $^{99\text{m}}\text{Tc}$ -MDP uptake depicts both components: the osteoblastic activity of the osteosarcoma cells themselves and the osteoblastic reaction of normal bone tissue surrounding the osteosarcoma (3). The second component is probably more prominent in more aggressively growing tumors. Furthermore, fast tumor growth implies neoangiogenesis with increased perfusion, which may also lead to higher  $^{99\text{m}}\text{Tc}$ -MDP uptake in biologically highly aggressive tumors (4). The same reasons seem to contribute to the similarity in  $^{99\text{m}}\text{Tc}$ -MDP uptake in various histologic subtypes of osteosarcoma. In contrast to  $^{99\text{m}}\text{Tc}$ -MDP bone scintigraphy,  $^{18}\text{F}$ -FDG PET directly assesses the cellular level of tumor metabolism, with only marginal influence from surrounding tissue.

The lack of correlation between  $^{18}\text{F}$ -FDG uptake and either the size or the histologic type of the primary lesion agrees with the findings of other studies—for instance, studies of patients with soft-tissue sarcoma (26)—and further underlines the fact that  $^{18}\text{F}$ -FDG uptake reflects an inherent biologic characteristic and does not relate to simply the morphologic parameters of the tumor. However, the lack of correlation between initial  $^{18}\text{F}$ -FDG uptake and grade of response is striking in the context of the significant correlation between  $^{18}\text{F}$ -FDG T/NT<sub>max</sub> and outcome. The response to neoadjuvant chemotherapy has been characterized as one of the most important prognostic factors (27,28). By measuring the change in  $^{18}\text{F}$ -FDG uptake during neoadjuvant chemotherapy, PET seems able to discriminate between good and poor responders, as assessed histologically (3,4,29).  $^{18}\text{F}$ -FDG uptake was not compared with individual outcome in those studies. The clinical impact of the combination of both the initial and the follow-up  $^{18}\text{F}$ -FDG uptake after neoadjuvant chemotherapy has to be evaluated prospectively with respect to patient outcome. Because of the relatively small population in the current study, a meaningful multivariate analysis was not feasible. Therefore, we could not establish whether  $^{18}\text{F}$ -FDG contributes as an additional independent prognostic factor, as has been proven in the case of pancreatic carcinoma and lung cancer (5,6,9). This issue should be addressed in further studies with larger, multicentric patient groups.

## CONCLUSION

$^{18}\text{F}$ -FDG uptake as measured by T/NT<sub>max</sub> using PET is predictive of outcome in osteosarcoma. Initial  $^{18}\text{F}$ -FDG uptake may add information useful for therapeutic decision making. There was a moderately positive relationship between  $^{18}\text{F}$ -FDG uptake and  $^{99\text{m}}\text{Tc}$ -MDP uptake.

## ACKNOWLEDGMENTS

The authors gratefully acknowledge Silke Steinhoff and Anika Brunegraf for their help with the  $^{18}\text{F}$ -FDG PET and bone scintigraphy quantifications; Matthias Kevric for his support with data collection; and all involved physicians, nurses, technicians, and members of the supporting services of the Department of Pediatric Hematology and Oncology and the Department of Nuclear Medicine.

## REFERENCES

- Schulte M, Brecht-Krauss D, Heymer B, et al. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. *J Nucl Med*. 2000;41:1695–1701.
- Kole AC, Nieweg OE, Hoekstra HJ, van Horn JR, Koops HS, Vaalburg W. Fluorine-18-fluorodeoxyglucose assessment of glucose metabolism in bone tumors. *J Nucl Med*. 1998;39:810–815.
- Franzius C, Sciuk J, Brinkschmidt C, Jürgens H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18-FDG-PET compared with histologically assessed tumor necrosis. *Clin Nucl Med*. 2000;25:874–881.
- Schulte M, Brecht-Krauss D, Werner M, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG-PET. *J Nucl Med*. 1999;40:1637–1643.
- Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on F-18-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. *J Clin Oncol*. 1999;17:3201–3206.
- Ahuja V, Coleman RE, Herndon J, Patz EFJ. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. *Cancer*. 1998;83:918–924.
- Maisey NR, Webb A, Flux GD, et al. FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. *Br J Cancer*. 2000;83:287–293.
- Dhital K, Saunders CAB, Seed PT, O'Doherty MJ, Dussek J. [F-18]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. *Eur J Cardiothorac Surg*. 2000;18:425–428.
- Zimny M, Fass J, Bares R, et al. Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma. *Scand J Gastroenterol*. 2000;35:883–888.
- Feine U, Lietzenmayer R, Hanke JP, Wöhrle H, Müller-Schauenburg W.  $^{18}\text{F}$ FDG whole-body PET in differentiated thyroid carcinoma: flipflop in uptake patterns of  $^{18}\text{F}$ FDG and  $^{131}\text{I}$  [in German]. *Nuklearmedizin*. 1995;34:127–134.
- Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma after polychemotherapy: study COSS 80. *J Cancer Res Clin Oncol*. 1983;106(suppl):21–24.
- Franzius C, Sciuk J, Daldrup-Link HE, Jürgens H, Schober O. FDG-PET for detection of osseous metastases from malignant primary bone tumors: comparison with bone scintigraphy. *Eur J Nucl Med*. 2000;27:1305–1311.
- Pietrzyk U, Herholz K, Fink G, et al. An iterative technique for three dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. *J Nucl Med*. 1994;35:2011–2018.
- Jones DN, McCowage GB, Sostman HD, et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET. *J Nucl Med*. 1996;37:1438–1444.
- Bielack S, Knop J, Delling G, Winkler K. Scintigraphic follow-up of osteosarcoma during neoadjuvant chemotherapy [in German]. *Nuklearmedizin*. 1988;27:237–241.
- Erlemann R, Sciuk J, Bosse A, et al. Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy. *Radiology*. 1990;175:791–796.
- Sachs L. U-Test von Wilcoxon, Mann and Whitney [U-test of Wilcoxon, Mann and Whitney]. In: Sachs L, ed. *Angewandte Statistik: Anwendung statistischer Methoden* [Applied Statistics: Application of Statistical Methods]. Berlin, Germany: Springer Verlag; 1984:230–238.
- Sachs L. Der Spearman'sche Rang-Korrelationskoeffizient [Spearman's correlation coefficient]. In: Sachs L, ed. *Angewandte Statistik: Anwendung statistischer Methoden* [Applied Statistics: Application of Statistical Methods]. Berlin, Germany: Springer Verlag; 1984:309–315.
- Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc*. 1958;53:457–481.
- Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. *Cancer Chemother Rep*. 1966;50:163–170.
- Bénard F, Serman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. *J Nucl Med*. 1999;40:1241–1245.
- Oshida M, Uno K, Suzuki M, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[ $^{18}\text{F}$ ]-D-glucose. *Cancer*. 1998;82:2227–2234.
- Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. *Radiology*. 2001;219:774–777.
- Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. *Radiology*. 1999;212:35–41.
- Shulkin BL, Hutchinson RJ, Castle VP, Yanik GA, Shapiro B, Sisson JC. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. *Radiology*. 1996;199:743–750.
- Schwarzbach MHM, Dimitrakopoulou-Strauss A, Willeke F, et al. Clinical value of [18-F]fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. *Ann Surg*. 2000;231:380–386.
- Fuchs K, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. *Ann Oncol*. 1998;9:893–899.
- Bielack S, Kempf-Bielack B, Schenzer D, et al. Neoadjuvant therapy for localized extremity osteosarcoma: experience of the Cooperative Osteosarcoma Study group COSS with 925 patients. *Klin Padiatr*. 1999;211:260–270.
- Nair N, Ali A, Green AA, et al. Response of osteosarcoma to chemotherapy: evaluation with F-18 FDG-PET scans. *Clin Positron Imaging*. 2000;3:79–83.